THE COST-EFFECTIVENESS OF SEQUENTIAL FIRST- AND SECOND-LINE TREATMENTS IN METASTATIC RENAL CELL CARCINOMA USING REAL-WORLD DATA AND A PATIENT-LEVEL SIMULATION MODEL

被引：0
|
作者：
de Groot, S. [1 ]
Blommestein, H. [1 ]
Redekop, W. [1 ]
Oosterwijk, E. [2 ]
Kiemeney, L. [2 ]
Uyl-de Groot, C. [1 ]
机构：
[1] Erasmus Univ, Rotterdam, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1625
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A587 / A587
页数：1
相关论文
共 50 条
  • [1] Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
    De Groot, S.
    Blommestein, H. M.
    Redekop, W. K.
    Sleijfer, S.
    Kiemeney, L. A. L. M.
    Oosterwijk, E.
    Uyl-de Groot, C. A.
    PLOS ONE, 2017, 12 (05):
  • [2] Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : E258 - E262
  • [3] Cost-effectiveness of second-line therapies in real-world setting: an economic evaluation of the EDGE study using patient level data
    McEwan, P.
    Evans, M.
    Foos, V.
    Paldanius, P. M.
    DIABETOLOGIA, 2015, 58 : S482 - S482
  • [4] First and Second-line Treatments in Metastatic Renal Cell Carcinoma
    Barragan-Carrillo, Regina
    Saad, Eddy
    Saliby, Renee-Maria
    Sun, Maxine
    Albiges, Laurence
    Bex, Axel
    Heng, Daniel
    Mejean, Arnaud
    Motzer, Robert J.
    Plimack, Elizabeth R.
    Powles, Thomas
    Rini, Brian I.
    Zhang, Tian
    Choueiri, Toni K.
    EUROPEAN UROLOGY, 2025, 87 (02) : 143 - 154
  • [5] Cost-effectiveness of first-line treatments in metastatic renal cell carcinoma
    Benton, John Z.
    Klaassen, Zachary
    Wallis, Christopher J. D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (02) : 285 - 286
  • [6] Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia
    Mihajlovic, Jovan
    Pechlivanoglou, Petros
    Sabo, Ana
    Tomic, Zdenko
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1909 - 1922
  • [7] Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
    Chay, Junxing
    Tung, Joshua Yi Min
    Su, Rebecca Jade
    Aslim, Edwin Jonathan
    Wong, Callix
    Swan, Georgia
    Chua, Wei Jin
    Ho, Henry Sun Sien
    Finkelstein, Eric Andrew
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1269 - 1277
  • [8] Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
    Chay, J.
    Su, R.
    Tung, J. Y. M.
    Aslim, E. J.
    Wong, C.
    Swan, G.
    Chua, W. J.
    Ho, S. S. H.
    Finkelstein, E. A.
    EUROPEAN UROLOGY, 2023, 83 : S52 - S52
  • [9] Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Zarba, Martin
    O'Sullivan, Dylan
    El Hajj Chehade, Razane
    Mckay, Rana R.
    Pal, Sumanta Kumar
    Beuselinck, Benoit
    Donskov, Frede
    Lalani, Aly-Khan A.
    Crumbaker, Megan
    Li, Haoran
    Alva, Ajjai Shivaram
    Powles, Thomas
    Takemura, Kosuke
    Kollmannsberger, Christian K.
    Wong, Shirley S.
    Wood, Lori A.
    de Velasco, Guillermo
    Cheung, Winson Y.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [10] The in vitro activity of Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma
    Zaccagnino, Angela
    Vynnytska-Myronovska, Bozhena
    Stoeckle, Michael
    Junker, Kerstin
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 102 - 102
12345